Pharmaceutical

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depression with the submission of an sNDA to the US FDA.

Jul 24, 2024 - 04:00
Johnson & Johnson submits sNDA for SPRAVATO to treat depression
Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depression with the submission of an sNDA to the US FDA.
Read the original article

Tags:

Previous Article

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

Next Article

Grünenthal gains Valinor Pharma and constipation drug Movantik

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rigosertib sodium by Traws Pharma for Epidermolysis Bul...

Apr 19, 2024

STAT+: Boston Scientific’s drug-coated balloon may reduce risk of heart attack

STAT+: Boston Scientific’s drug-coated balloon may redu...

Oct 26, 2023

HHS gives thumbs down to bluebird’s fertility support programme

HHS gives thumbs down to bluebird’s fertility support p...

Jul 24, 2024